Close Menu

NEW YORK – Seattle Genetics said Wednesday that its Phase II HER2CLIMB trial for tucatinib in treating HER2-positive metastatic breast cancer yielded positive data. The results were presented at the 2019 San Antonio Breast Cancer Symposium and the accompanying study was published in the New England Journal of Medicine.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.